[18F]氟普沙定用于去甲肾上腺素转运体PET的首人体评估:生物分布、剂量学与安全性
本研究为前瞻性首人体研究,4名健康成人志愿者接受[18F]氟普沙定(101.8-204.0 MBq)全身动态PET/CT,评估安全性、生物分布、辐射剂量学及成像特征。结果显示以肾脏清除为主,膀胱壁和肾脏剂量最高,有效剂量为21.6±1.5 µSv/MBq,心肌摄取清晰且靶本比良好,无严重不良事件。
要点
- 4名健康志愿者接受[18F]氟普沙定,无严重不良事件。
- 有效剂量为21.6±1.5 µSv/MBq,与典型18F PET药物相当。
- 心肌摄取清晰可见,延迟时间点靶本比良好。
核心结论
- [18F]氟普沙定显示清晰心肌摄取、可接受的辐射剂量学及无严重不良事件的早期安全性特征。
研究设计与样本
- 前瞻性首人体研究,纳入4名健康成人志愿者,接受[18F]氟普沙定101.8-204.0 MBq。
- 注射后1至232分钟内进行10次全身动态PET/CT采集,并监测生命体征、实验室检查和不良事件。
- 使用OLINDA/EXM v2.0从时间积分活度估算器官吸收剂量和有效剂量。
主要发现
- 生物分布显示以肾脏清除为主,成像窗口内未观察到胆道排泄。
- 器官剂量最高为膀胱壁和肾脏,肝脏、甲状腺、唾液腺和心肌也有摄取。
- 有效剂量为21.6±1.5 µSv/MBq。
- 全身图像上心肌摄取清晰可见,延迟时间点靶本比良好,符合NET生物学特征。
临床怎么用
- 可考虑用于心脏交感神经成像,延迟时间点成像窗口具有良好靶本比。
- 辐射剂量与典型18F PET药物相当,支持进一步临床研究。
局限性
- 研究仅纳入4名健康志愿者,样本量小。
- 未报告诊断效能或患者数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current norepinephrine transporter (NET) tracers used for cardiac sympathetic imaging and oncology are limited by radiosynthesis complexity, suboptimal image quality, or operational constraints. [18F]fluproxadine (formerly [18F]AF78) was developed to address these limitations by providing high NET affinity, favorable biodistribution, and an operationally straightforward radiosynthesis. We therefore conducted the first-in-human evaluation of this new class of [18F] labeled NET PET tracer to assess its safety, biodistribution, radiation dosimetry, and imaging characteristics. PATIENTS AND METHODS: In a prospective study, 4 healthy adult volunteers received [18F]fluproxadine (101.8-204.0 MBq). Dynamic whole-body PET/CT acquisitions were obtained 10 times from 1 to 232 minutes postinjection, and vital signs, laboratory tests, and adverse events were monitored. Time-activity curves were generated for major organs, including myocardium from the whole-body scans, and organ-absorbed doses and effective dose were estimated using OLINDA/EXM v2.0 from time-integrated activities. Myocardial uptake and target-to-background behavior were assessed using semiquantitative methods. Radiosynthesis performance and key operational steps were documented to assess practical scalability. RESULTS: Radiosynthesis of [18F]fluproxadine was operationally straightforward with encouraging yields and fewer specialized steps than some legacy tracers. Imaging was completed without serious adverse events. Biodistribution showed predominant renal clearance; biliary excretion was not observed within the imaging window. Highest organ doses were to the urinary bladder wall and kidneys, with additional uptake in liver, thyroid, salivary glands, and myocardium. The effective dose was 21.6±1.5 µSv/MBq. Myocardial uptake was clearly visualized on whole-body images with favorable target-to-background characteristics at delayed time points, consistent with NET biology and supporting practical cardiac imaging windows. CONCLUSIONS: [18F]fluproxadine demonstrated clear myocardial uptake, acceptable radiation dosimetry comparable to typical 18F PET agents, and an early safety profile without serious adverse events.
引用
- Yamane T, Iimori H, Akamatsu G, et al. First-In-Human Evaluation of [18F]Fluproxadine for Norepinephrine Transporter PET: Biodistribution, Dosimetry, and Safety. Clin Nucl Med. 2026. PMID: 42247617. doi:10.1097/RLU.0000000000006504
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。